Phase II Study of Clofarabine in Pediatric Acute Myelogenous Leukemia (AML) Patients
Status:
Completed
Trial end date:
2004-08-01
Target enrollment:
Participant gender:
Summary
Clofarabine (injection) is approved by the Food and Drug Administration (FDA) for the
treatment of pediatric patients 1 to 21 years old with relapsed acute lymphoblastic leukemia
(ALL) who have had at least 2 prior treatment regimens.
The purpose of this study is to determine whether Clofarabine is safe and effective in the
treatment of Acute Myelogenous Leukemia (AML.)